Microbix Biosystems Inc T.MBX

Stats

[lscfa]

 

Qtr ending	Revenue	Net income	cfo	Adj ebitda	Gross margin	Cogs	ebitda margin
Dec 22	2,502,072	(1,299,262)	(808,050)	(785,916)	47.4%	1,316,097	(31.4%)
Sep 22	4,329,052	(464,080)	83,202	217,891	46.7%	2,308,513	5.0%
Jun 22	5,011,025	638,502	1,169,004	1,260,806	55.2%	2,244,879	25.2%
Mar 22	4,880,564	733,489	1,227,810	1,345,350	63.9%	1,764,265	27.6%
Dec 21	4,855,600	880,778	1,325,273	1,472,259	66.4%	1,633,742	30.3%
Sep 21	5,629,694	778,930	1,759,282	2,140,288	57.7%	2,383,971	38.0%
Jun 21	5,451,834	1,516,178	1,937,797	1,909,219	63.2%	2,006,020	35.0%
Mar 21	4,353,773	807,463	1,189,857	1,368,244	59.8%	1,748,668	31.4%
Dec 20	3,157,659	130,819	438,275	618,712	55.3%	1,410,361	19.6%

[lscfa]

More stats.....   Qtr ending  Antigen QAP DxTM Royalties Total Revenue Dec 22 1,003,807 1,333,503 0 164,762 2,502,072 Sept 22

[lscfa]

if antigen orders were deferred does this mean the next qtr will be above average? $3.5 million? Mgmt should have given better guidance.

[lscfa]

Deferred revenue went up by $927,520. Delayed orders prepaid?     

[Mbxwatcher]

I'd guess the QAPS deal There were guaranteed volumes which are probably deferred to late start up